Omeprazole, clarithromycin and furazolidone for the eradication of <i>Helicobacter pylori</i> in patients with duodenal ulcer

Dani, Renato; Queiroz, Dulciene Maria Magalhães; Dias, Mário; Franco, J. M. M.; Magalhães, Lívia de Castro; Mendes, Graziele; Moreira, Liano Sia; Castro, Lúcia Porto Fonseca de; Toppa, Nivaldo Hartung; Rocha, Gifone A.; Cabral, Mônica Maria Demas Álvares; Salles, P. G. O.

doi:10.1046/j.1365-2036.1999.00653.x

Cited by 42 publications

(46 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A associação de furazolidona, claritromicina e IBP é particularmente útil para pacientes com impedimento para o uso de amoxicilina, com trabalhos nacionais evidenciando excelente índice de erradicação do microrganismo, embora curse com número algo maior de efeitos adversos (6) . A associação de tetraciclina, furazolidona e IBP foi incluída como forma de oferecer opção terapêutica envolvendo antimicrobianos que hoje acham-se disponíveis para a população na rede do Sistema Único de Saúde.…”

Section: Comentáriosunclassified

II Consenso Brasileiro sobre Helicobacter pylori

Coelho

Zaterka

2005

Arq. Gastroenterol.

View full text Add to dashboard Cite

INTRODUÇÃODesde sua identificação por MARSHALL e WARREN (13) , em 1982, O Helicobacter pylori (HP) rapidamente se tornou alvo de incontáveis estudos microbiológicos, histológicos, epidemiológicos, imunológicos, ecológicos e clínicos, entre outros. Conseqüentemente, em curto período de tempo, os avanços do conhecimento na área puderam ser utilizados, de forma revolucionária, na prática médica diária de clínicos e gastroenterologistas. O alcance desta descoberta pode ser avaliado pelo resultado de inquérito recente entre gastroenterologistas, onde tal descoberta foi considerada a mais importante da especialidade no último século (8) .Com o objetivo de orientar os médicos nas várias questões relacionadas ao manuseio da infecção pelo HP, diferentes reuniões de consenso têm sido realizadas em todo o mundo (1,5,10,12,15,23) . No Brasil, em 1995, durante o Congresso Panamericano de Enfermedades Digestivas, realizado em Belo Horizonte, MG, foi realizado o "Consenso Nacional sobre H. pylori e afecções associadas" (2) .A

show abstract

Section: Comentáriosunclassified

II Consenso Brasileiro sobre Helicobacter pylori

Coelho

Zaterka

2005

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…The treatment is performed for 7 days, the doses of furazolidone used range from 100 mg (children) to 400 mg/day, with frequent adverse effects, particularly gastrointestinal (28,35,63,107,128) . A systematic review and meta-analysis of the effects of furazolidone and nitrofurantoinic derivatives in eradicating H pylori showed that schemes using such drugs had more frequent adverse effects and slightly less effective eradication rates when compared with the classic triple therapy (12) .…”

Section: Statement 29mentioning

confidence: 99%

“…In reality, meta-analysis studies have shown a 4% gain by extending to 10 days and 5% with 14 days (15,60,64,91) . For patients with a possible or proven history of penicillin allergy to the scheme described above is recommended replacing amoxicillin with the furazolidone 200 mg twice a day (31,35) . Other options include using metronidazole or levofloxacin instead of amoxicillin or adopting schemes employing tetracycline and metronidazole and bismuth salts (72,73,171) .…”

Section: Statement 27mentioning

confidence: 99%

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Coelho

Maguinilk

Zaterka³

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the Second Brazilian Consensus Conference on Helicobacter pylori Infection held in 2004, in São Paulo, SP, Brazil, and justify a third meeting to establish updated guidelines on the current management of H. pylori infection. The Third Brazilian Consensus Conference on H pylori Infection was organized by the Brazilian Nucleus for the Study of Helicobacter, a Department of the Brazilian Federation of Gastroenterology and took place on April 12-15, 2011, in Bento Gonçalves, RS, Brazil. Thirty-one delegates coming from the five Brazilian regions and one international guest, including gastroenterologists, pathologists, epidemiologists, and pediatricians undertook the meeting. The participants were allocated in one of the five main topics of the meeting: H pylori, functional dyspepsia and diagnosis; H pylori and gastric cancer; H pylori and other associated disorders; H pylori treatment and retreatment; and, epidemiology of H pylori infection in Brazil. The results of each subgroup were submitted to a final consensus voting to all participants. Relevant data were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded. Seventy per cent and more votes were considered as acceptance for the final statement. This article presents the main recommendations and conclusions to guide Brazilian doctors involved in the management of H pylori infection.

show abstract

“…Furazolidone has been demonstrated to be an effective drug in H. pylori treatment in Brazil, with eradication rates in adult patients up to 90% by intention to treat. 11 In children, its efficacy is lower, but it is at least similar to that exhibited by the traditional Maastricht regimen. 5,7 Furazolidone has not been tested in conjunction with tetracycline in children, and this is the main contribution of this study.…”

Section: Discussionmentioning

confidence: 99%

Furazolidona, tetraciclina e omeprazol: uma alternativa de baixo custo para erradicação de Helicobacter pylori em crianças

Machado¹,

Silva²,

Viriato³

2008

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objectives: To evaluate furazolidone, tetracycline and omeprazole as first line therapy for Helicobacter pylori in children with digestive symptoms. Methods:Prospective and consecutive open trial. The study included patients older than 8 years old with functional dyspepsia, functional abdominal pain, severe histological abnormalities (intestinal metaplasia, gastric atrophy or mucosa-associated lymphoid tissue lymphoma) or peptic ulcer. H. pylori status was defined based both upon histology and rapid urease test. Drug regimen was a 7-day course of omeprazol, tetracycline (or doxycycline) and furazolidone twice daily. Eradication was assessed by upper endoscopy 2 months after treatment (histology and rapid urease test).Further clinical evaluation was done 7 days and 2 months after treatment.Results: Thirty-six patients (21 female/15 male) were included. Age ranged from 8 to 19 years (mean 12.94±2.89 years). On intention-to-treat analysis (n = 36), eradication rate was 83.3% (95%CI 77.1-89.5) whereas in per-protocol analysis (n = 29), it was 89.7% (95%CI 84.6-94.7). Compliance was better when doxycycline was used, but the success rates were similar for the two tetracyclines. There was no variable associated with treatment failure. Side effects were reported in 17 patients (47.2%), mainly abdominal pain (11/30.5%), nausea (seven/19.4%) and vomiting (five/ 13.9%). Conclusion:Triple therapy with furazolidone and tetracycline is a low-cost alternative regimen to treat H. pylori infection.J Pediatr (Rio J). 2008;84(2):160-165: Furazolidone, tetracycline, Helicobacter pylori treatment, child, clinical trial.

show abstract

Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer

Abstract: Our results demonstrate that clarithromycin and furazolidone in combination with omeprazole are a good alternative for H. pylori eradication in Brazilian patients with duodenal ulcer.

Cited by 42 publications

References 18 publications

II Consenso Brasileiro sobre Helicobacter pylori

II Consenso Brasileiro sobre Helicobacter pylori

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Furazolidona, tetraciclina e omeprazol: uma alternativa de baixo custo para erradicação de Helicobacter pylori em crianças

Contact Info

Product

Resources

About